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1726-4Luteal phase support with gonadotropin-releasing hormone agonistKung et al1 authored a valuable article entitled “Luteal
phase support with decapeptyl improves pregnancy outcomes
in ICSI with basal FSH >8 mIU/mL or mature oocytes 3”.
This retrospective study enrolled 240 patients who underwent
intracytoplasmic sperm injection (ICSI). One hundred and
forty-seven patients were in the decapeptyl group and 93
patients were in the control group. The authors investigated
the effect of decapeptyl as an additional luteal phase support
(LPS) in in vitro fertilization (IVF) cycles and tested which
subgroup would benefit from the treatment.1 We recognize the
probity of this publication.
Luteal phase defect is a common problem encountered
during IVF cycles. In the past, several theories have been
proposed such as (1) defective corpora lutea formed from the
remnants of the aspirated follicles and (2) prolonged pituitary
downregulation by the gonadotropin-releasing hormone
(GnRH) agonist. Both of these theories attempt to explain
premature luteolysis during IVF cycles; however, there has
been a lack of subsequently published studies with sufficiently
reliable evidence to support these theories.2 By contrast, a new
hypothesis of multiple corpora lutea has been proposed. This
hypothesis is based on the effect occurring after ovarian
hyperstimulation wherein more steroids are subsequently
produced, which suggests that the negative feedback on the
pituitary gland inhibits luteinizing hormone release. Premature
luteolysis arise from the negative feedback by high concen-
trations of steroids caused by multiple corpora lutea.2 How-
ever, there is no doubt that LPS is essential to enhance
reproductive outcomes in IVF cycles. Progesterone and human
chorionic gonadotropin have served as popular and effective
LPS agents.2 In addition, Tesarik et al3 described using a
GnRH agonist as LPS to improve the implantation rate,
pregnancy rate, and live birth rate. Several studies4e7 sub-
sequently support the results obtained by Tesarik et al,3
whereas other studies show dissimilar conclusions.8,9 Taken
together, two systemic reviews, which include meta-analyses,
demonstrate that administering a luteal phase single-dose
GnRH agonist can significantly ameliorate IVF outcomes.2,10
Kung et al1 confirmed in their study the beneficial effect of
luteal phase single-dose decapeptyl administration on the
implantation rate (24.5% vs. 17.0%; p ¼ 0.023), clinical
pregnancy rate (49.0% vs. 33.3%; p ¼ 0.023), and live birth
rate (41.5% vs. 28.0%; p ¼ 0.039).
The precise mechanism of how a GnRH agonist exerts its
effect in the luteal phase remains unclear. Some studiesx.doi.org/10.1016/j.jcma.2014.06.002
901/Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Asssuggest that a GnRH agonist may have a role in regulating
embryoeendometrial interactions.11,12 Metallinou et al13
however showed that GnRH agonists promote apoptosis of
granulosa luteal cells and directly inhibit progesterone pro-
duction in human granulosa luteal cells. Gonadotropin-
releasing hormone agonists seem to have a positive effect on
the embryo and endometrium, but a negative effect on the
corpus luteum.
Despite controversial clinical results11e13 and possible
mechanisms, the previous literature findings indicate added
beneficial effects and more positive mechanisms when a
GnRH agonist is administered as LPS.11,12 A GnRH agonist
administered for specific groups such as LPS can supposedly
generate a subsequent improved benefit.
A GnRH agonist, which can act on embryos and on the
endometrium through GnRH agonist receptors,13 theoret-
ically may fail to function properly because of prolonged and
persistent downregulation of the GnRH receptors during IVF
cycles with a long protocol. Therefore, the extension of the
GnRH agonist through the luteal phase in IVF cycles does not
enhance reproductive outcomes.14,15 In 2006, a prospective
randomized study revealed that the administration of the
luteal phase GnRH agonist enhances ICSI clinical outcomes
in GnRH agonist-treated and GnRH antagonist-treated ovar-
ian stimulation cycles.4 However, later studies demonstrate
that luteal phase GnRH agonists mostly work within the
GnRH antagonist protocol,6,10 but not in the long GnRH
agonist protocol.8,9
In the Kung et al1 study, the investigators verified that
clinical pregnancy rate and live birth rate significant increased
with the GnRH antagonist protocol ( p ¼ 0.025 and p ¼ 0.035,
respectively), but not with the long GnRH agonist protocol
( p ¼ 0.288 and p ¼ 0.367, respectively). The Kung et al1
study moreover revealed that patients with higher basal FSH
(>8 mIU/mL) or reduced numbers of mature oocytes (3)
may have a better prognosis after using luteal phase decap-
eptyl.1 However, because of the following reasons, Kung's
proposals may require more substantial evidence. First, the
decapeptyl was theoretically administered during the luteal
phase, which may affect the embryo, endometrium, or corpus
luteum, but not the ovarian reserve. Second, in the Tesarik
et al3 study, the administration of a luteal phase GnRH agonist
also was beneficial in the oocyte donation program. Thus, the
patients who had diminished ovarian reserve with better
reproductive outcomes may have had this as a benefit ofociation. All rights reserved.
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Table 3 in the Kung et al1 study, the researchers tried to clarify
the impact of reduced mature oocytes. In addition, Qublan
et al7 demonstrated that patients with a thin endometrium
(7 mm) on the day of oocyte retrieval had increased
implantation and pregnancy rates from the administration of a
luteal phase GnRH agonist. However, it is difficult to make a
conclusion from such small sample size. Additional large-
scale randomized controlled trials are needed.
Luteal phase GnRH agonist administration probably gives
rise to ovarian hyperstimulation syndrome (OHSS) by raising
the human chorionic gonadotropin level.4 The OHSS rate
seems to be less frequently mentioned in previous studies.2e10
In the Kung et al1 study, there was no increased OHSS rate in
the decapeptyl group during IVF cycles. Some studies show
that multiple pregnancy rates seemed to be higher after luteal
phase GnRH agonist administration, possibly because of the
higher implantation rate.3,6 However, a Cochrane review
revealed no significant difference in multiple pregnancy rates
between the progesterone group and the progesterone plus
GnRH agonist group.2 Despite the aforementioned results, the
risk should be always considereddeven though we prescribed
GnRH agonist as LPS.
In conclusion, the administration of a luteal phase GnRH
agonist improved IVF outcomes for the most part. To analyze
the subgroups, patients with GnRH antagonist stimulation
protocol seem to have a proven record of patient benefits.
However, other subgroups such as women with diminished
ovarian reserve or women with a thin endometrium lack
strong support. The mechanism and a standard protocol are
needed so that large scale, randomized controlled trials can
occur.Conflicts of interest
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